MGMT RESEARCH / SOURCE NOTES
About these references.
These are concise original references, not a complete reproduction of every source guide. Captured values are attributed; unresolved source claims and missing information are listed below.
Research reference only. Source-reported examples and schedules are not dosing recommendations from MGMT Research. They do not establish safety or suitability. Prescribed medication decisions belong with a licensed clinician and the current product label.
Peptide calculator 1 notes
View reference → · Source ↗- Some reference tables round mL and units separately. Exact arithmetic results in this preview are not a certification of identical source display rounding.
Reconstitution & reverse calculation 1 notes
View reference → · Source ↗- Product-specific mixing and storage instructions still require review; no universal storage period is adopted.
Blend calculator 1 notes
View reference → · Source ↗- This preview accepts the combined target, not a component-specific target. Confirm the labelled ratio.
HGH IU calculator 1 notes
View reference → · Source ↗- The IU-to-mg relationship is specific to the referenced somatropin convention.
HCG IU calculator 1 notes
View reference → · Source ↗- Source storage windows vary by branded product. They are recorded for review and are not a general expiry instruction.
Peptide molecular weight 1 notes
View reference → · Source ↗- Exact source residue constants, pKa values and algorithm were not retrievable. Molecular results remain disabled rather than inventing formula parity.
mcg ↔ mg converter 1 notes
View reference → · Source ↗- The source describes a 10× unit-confusion error while the direct mg/mcg factor is 1,000. This claim is flagged, not silently rewritten.
Semaglutide 1 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
Tirzepatide 2 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
- Source tables independently round concentration, mL and syringe units; preserve inputs and flag display-rounding differences for approval.
Retatrutide 2 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
- Source tables independently round concentration, mL and syringe units; preserve inputs and flag display-rounding differences for approval.
Cagrilintide 2 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
- Rendered source widget exposes generic 5 mg / 2 mL / 250 mcg values; article example differs. The example field records the article, not verified interactive defaults.
Liraglutide 3 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
- Rendered source widget exposes generic 5 mg / 2 mL / 250 mcg values; article example differs. The example field records the article, not verified interactive defaults.
- Source tables independently round concentration, mL and syringe units; preserve inputs and flag display-rounding differences for approval.
BPC-157 1 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
TB-500 1 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
Thymosin Alpha-1 2 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
- Rendered source widget exposes generic 5 mg / 2 mL / 250 mcg values; article example differs. The example field records the article, not verified interactive defaults.
KLOW 1 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
KPV 1 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
ARA-290 2 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
- Source tables independently round concentration, mL and syringe units; preserve inputs and flag display-rounding differences for approval.
Ipamorelin 2 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
- Source tables independently round concentration, mL and syringe units; preserve inputs and flag display-rounding differences for approval.
Tesamorelin 1 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
CJC-1295 without DAC 1 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
CJC-1295 with DAC 1 notes
View reference → · Source ↗- Source page could not be retrieved after direct open, directory-link click, trailing-slash retry and search. No numerical defaults inferred.
Sermorelin 2 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
- Rendered source widget exposes generic 5 mg / 2 mL / 250 mcg values; article example differs. The example field records the article, not verified interactive defaults.
AOD-9604 1 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
Hexarelin 2 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
- Rendered source widget exposes generic 5 mg / 2 mL / 250 mcg values; article example differs. The example field records the article, not verified interactive defaults.
GHRP-2 1 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
GHRP-6 2 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
- Rendered source widget exposes generic 5 mg / 2 mL / 250 mcg values; article example differs. The example field records the article, not verified interactive defaults.
IGF-1 LR3 2 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
- Source calculation uses BAC water but source preparation notes mention dilute acid, including 0.6% acetic acid for some suppliers. Formula does not establish diluent suitability.
MOTS-c 1 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
Epithalon 1 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
NAD+ 2 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
- Source tables independently round concentration, mL and syringe units; preserve inputs and flag display-rounding differences for approval.
SS-31 1 notes
View reference → · Source ↗- Source page could not be retrieved after direct open, directory-link click, trailing-slash retry and search. No numerical defaults inferred.
Semax 2 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
- Source tables independently round concentration, mL and syringe units; preserve inputs and flag display-rounding differences for approval.
Selank 2 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
- Rendered source widget exposes generic 5 mg / 2 mL / 250 mcg values; article example differs. The example field records the article, not verified interactive defaults.
DSIP 2 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
- Rendered source widget exposes generic 5 mg / 2 mL / 250 mcg values; article example differs. The example field records the article, not verified interactive defaults.
PT-141 1 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
Kisspeptin 1 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
GHK-Cu 1 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
Melanotan II 2 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
- Source tables independently round concentration, mL and syringe units; preserve inputs and flag display-rounding differences for approval.
Glutathione 1 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
GLOW 3 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
- Source tables independently round concentration, mL and syringe units; preserve inputs and flag display-rounding differences for approval.
- Source introduction gives 1.75 mg = 0.0875 mL = 8.75 units; its animated equation displays 0.087 mL and 8.8 units, while quick answers show 0.09 mL. No silent normalization approved.
CJC-1295 / Ipamorelin 2 notes
View reference → · Source ↗- Main worked example and first reference-table inputs captured. Complete article, schedule, storage and all secondary-example numeric parity have not been audited.
- Rendered source widget exposes generic 5 mg / 2 mL / 250 mcg values; article example differs. The example field records the article, not verified interactive defaults.
Reconstitution: record the setup 1 notes
View reference → · Source ↗- The source generalizes a 28-day window to many compounded peptides; product-specific validation is required before carrying that claim into MGMT content. No universal expiry has been assigned.
BAC water: composition and calculation 1 notes
View reference → · Source ↗- Source refrigeration and extended-use claims are unverified and withheld for approval. Shortage and prescription-availability claims need current jurisdiction-specific checking. Numeric facts are source observations, not MGMT specifications.
Keep each vial’s record separate 1 notes
View reference → · Source ↗- Source schedule, cost and complexity thresholds are not validated clinical or financial standards. They are retained here for review but omitted from the draft; schedule wording requires explicit review.
Keep storage instructions with the vial record 1 notes
View reference → · Source ↗- The reference range is not a universal storage specification for all MGMT compounds.
Check units before trusting the result 1 notes
View reference → · Source ↗- The source’s 14% example is rounded. Its FAQ incorrectly implies capacity alone changes draw volume; that statement is withheld pending approval. Dead-space claims require equipment-specific review.
Connect mass to volume through concentration 1 notes
View reference → · Source ↗- Additional clinical-range examples are not reproduced or verified. Source describes 0.25–2.4 mg as 10× and underdosing as mostly harmless; neither claim is adopted.
BPC-157 + TB-500: separate vials and blends 3 notes
View reference → · Source ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
- Source describes inconsistent BPC-157 frequency: daily/twice daily versus daily/EOD. No frequency was silently chosen.
- Some TB-500 source table targets exceed total vial content or the displayed syringe capacity.
BPC-157 + GHK-Cu: concentration comparison 1 notes
View reference → · Source ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
Semax + Selank: two independent calculations 3 notes
View reference → · Source ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
- Source rounds mL separately from U-100 units. Do not silently replace its displayed values. Exact-volume calculator behavior and source-display precision require review.
- The main Semax table uses 3 mL; introductory example uses 2 mL. These are distinct setups, not interchangeable defaults.
Ipamorelin + CJC-1295: vial math 2 notes
View reference → · Source ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
- Source rounds mL separately from U-100 units. Do not silently replace its displayed values. Exact-volume calculator behavior and source-display precision require review.
Tesamorelin + Ipamorelin: mass and volume 3 notes
View reference → · Source ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
- Source rounds mL separately from U-100 units. Do not silently replace its displayed values. Exact-volume calculator behavior and source-display precision require review.
- The source ties 1.4 mg to Egrifta SV. It must not be generalized to other formulations; primary-label review remains required.
GHRP-2 + CJC-1295: separate inputs 2 notes
View reference → · Source ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
- Source contains comparative physiological claims and simultaneous-use guidance that have not been independently substantiated here.
MOTS-c + AOD-9604: checking measurement scales 2 notes
View reference → · Source ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
- The 5 mg vial / 10 mg target example exceeds available vial mass. Do not present it as an achievable single-vial draw.
Wegovy: source schedule reference 3 notes
View reference → · Source ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
- Source is a secondary summary; current product presentation, indication and prescribing details must be reconciled with the official label before publication.
- Source treats 2.4 mg as the upper Wegovy schedule. Current manufacturer PI search also lists WEGOVY HD 7.2 mg and tablets; source scope is incomplete. Preserve source values pending explicit approval. Primary: https://www.novo-pi.com/wegovy.pdf
Ozempic: source schedule reference 3 notes
View reference → · Source ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
- Source is a secondary summary; current product presentation, indication and prescribing details must be reconciled with the official label before publication.
- Source semaglutide reference table includes 1.7 and 2.4 mg despite its Ozempic schedule ending at 2.0 mg. Retain product-specific context; do not treat every reference-table target as an Ozempic dose.
Mounjaro: source schedule reference 3 notes
View reference → · Source ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
- Source is a secondary summary; current product presentation, indication and prescribing details must be reconciled with the official label before publication.
- Source presents the brand as pens and contrasts it with compounded vials. Current official information includes branded vial presentations, so that framing is incomplete. Primary: https://pi.lilly.com/us/mounjaro-uspi.pdf
Zepbound: source schedule reference 3 notes
View reference → · Source ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
- Source is a secondary summary; current product presentation, indication and prescribing details must be reconciled with the official label before publication.
- Source presents the brand as pens and contrasts it with compounded vials. Current official information includes branded vial presentations, so that framing is incomplete. Primary: https://pi.lilly.com/us/zepbound-uspi.pdf
Saxenda: source schedule reference 2 notes
View reference → · Source ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
- Source is a secondary summary; current product presentation, indication and prescribing details must be reconciled with the official label before publication.
Tirzepatide: source schedule and units 3 notes
View reference → · Source ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
- Source rounds mL separately from U-100 units. Do not silently replace its displayed values. Exact-volume calculator behavior and source-display precision require review.
- Last two rows exceed the stated vial mass; several exceed 1 mL. Preserve numbers but mark these constraints in review.
Semaglutide: source schedule and units 2 notes
View reference → · Source ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
- Source states a 2.4 mg Wegovy maximum; current manufacturer material also lists WEGOVY HD 7.2 mg. No source value was changed. Primary: https://www.novo-pi.com/wegovy.pdf
Retatrutide: source schedule awaiting retrieval 1 notes
View reference → · Source ↗- Source URL is linked from the directory, but opening it repeatedly returned cache miss. No schedule, starting dose or titration values have been invented. Content is blocked pending retrieval.
Semaglutide and tirzepatide: reference comparison 2 notes
View reference → · Source ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
- Source range is not a complete current product-label summary. See Wegovy review issue.
Retatrutide and tirzepatide: reference comparison 2 notes
View reference → · Source ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
- Research ranges are not approved prescribing instructions. Regulatory status needs current primary-source verification before publication.
BPC-157 and TB-500: reference comparison 2 notes
View reference → · Source ↗- Source numeric coverage is partial: selected reference values are preserved; all additional source tables and examples still require reconciliation before claiming full fidelity.
- Source half-life descriptions and use ranges have not been independently validated here. Do not present them as established clinical dosing.